Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Director | June 16, 2020 | June 19, 2020 |
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Chief Financial Officer | July 01, 2026 | August 05, 2026 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | November 04, 2024 | November 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date June 16, 2020 · Filed June 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-06-15 | Direct | 230,000 |
Reported balance
After 2020-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 230,000 · Balance 230,000 F1: The option is durational-based. 80,000 option shares vested on the date of grant and the remaining 150,000 option shares vest and become exercisable on June 16, 2021, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is durational-based. 80,000 option shares vested on the date of grant and the remaining 150,000 option shares vest and become exercisable on June 16, 2021, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service.
Inhibitor Therapeutics, Inc.
Report date July 01, 2026 · Filed August 05, 2026
Jointly reported with Black Robe Capital LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,901,057 |
Reported balance
After 2026-07-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-07-01 · Gift · Disposed 3,200,000 · Balance 19,901,057 |
Lunai Bioworks Inc.
Report date November 04, 2024 · Filed November 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2034-11-04 | Direct | 120,968 |
Reported balance
After 2024-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-04 · Grant · Acquired 120,968 · Balance 120,968 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Aug 5, 2026 01:03 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GiftCommon Stock | 3,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-036080 · ownership.xml · nonDerivative · entry 1 Black Robe Capital LLC · CIK 0001977553 · 10% owner MCNULTY JAMES A · CIK 0001275857 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,901,057 Read SEC document |
| December 02, 2024 Filed Feb 20, 2025 02:28 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-007628 · ownership.xml · nonDerivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946,135 Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 20:25 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 120,968 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001731122-24-001719 · ownership.xml · derivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,968 Underlying: Common stock · 120,968 shares Expires 2034-11-04 Read SEC document |
| March 16, 2024 Filed May 16, 2024 17:34 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001493152-24-020169 · ownership.xml · derivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · CHIEF FINANCIAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-03-16 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on March 16, 2024 pursuant to the Issuer's 2014 Equity Incentive Plan. The common stock options vested immediately. Read SEC document |
| May 05, 2023 Filed May 17, 2023 23:46 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | OtherCommon Stock | 20,101,057 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013201 · doc4.xml · nonDerivative · entry 3 MCNULTY JAMES A · CIK 0001275857 · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 26,101,057 F1 · kind: Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC. F2 · ownership.nature: Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares. Read SEC document |
| May 05, 2023 Filed May 17, 2023 23:46 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | OtherCommon Stock | 398,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013201 · doc4.xml · nonDerivative · entry 2 MCNULTY JAMES A · CIK 0001275857 · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,135 F1 · kind: Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC. F2 · ownership.direct: Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares. Read SEC document |
| May 05, 2023 Filed May 17, 2023 23:46 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | OtherCommon Stock | 79,627,069 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013201 · doc4.xml · nonDerivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC. F2 · ownership.nature: Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares. Read SEC document |
| June 16, 2020 Filed Jun 19, 2020 00:44 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantCommon Stock · Derivative | 230,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001510964-20-000052 · wf-form4_159252746741724.xml · derivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: The option is durational-based. 80,000 option shares vested on the date of grant and the remaining 150,000 option shares vest and become exercisable on June 16, 2021, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. Read SEC document |
| February 05, 2018 Filed Jun 6, 2018 17:34 UTC | CV Sciences, Inc. CANV · Entity 8316 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001683168-18-001601 · mcnulty_f4.xml · derivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-02-04 F1 · derivative.exercise_date: This option is durational-based and vests as follows: the option shares vest in twelve (12) equal monthly installments measured from January 1, 2018. Read SEC document |
| March 17, 2017 Filed May 26, 2017 23:35 UTC | CV Sciences, Inc. CVSI · Entity 8316 | OtherCommon Stock | 1,450,500 | $0.41 | $599,056.50 |
DisclosureSEC source: 0001144204-17-029917 · v467793_4.xml · nonDerivative · entry 2 MCNULTY JAMES A · CIK 0001275857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,545,500 F1 · kind: The shares were issued pursuant to that certain Agreement and Plan of Reorganization, dated as of December 30, 2015, by and among CannaVEST Corp., CANNAVEST Merger Sub, Inc., CANNAVEST Acquisition LLC, CanX, Inc, and The Starwood Trust, as the Shareholder Representative. Read SEC document |
| October 05, 2016 Filed May 26, 2017 23:35 UTC | CV Sciences, Inc. CVSI · Entity 8316 | OtherCommon Stock | 45,000 | $0.41 | $18,225.00 |
DisclosureSEC source: 0001144204-17-029917 · v467793_4.xml · nonDerivative · entry 1 MCNULTY JAMES A · CIK 0001275857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 F1 · kind: The shares were issued pursuant to that certain Agreement and Plan of Reorganization, dated as of December 30, 2015, by and among CannaVEST Corp., CANNAVEST Merger Sub, Inc., CANNAVEST Acquisition LLC, CanX, Inc, and The Starwood Trust, as the Shareholder Representative. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.